Skip to content
Government QLD, Medical Health Aged Care

Free influenza vaccinations from Queensland pharmacists

Pharmaceutical Society of Australia (PSA) 2 mins read

17 July 2023

The Pharmaceutical Society of Australia (PSA) welcomes the Queensland Government's announcement of state-wide, no-cost influenza vaccinations for Queenslanders from this Saturday, 22 July.

PSA Queensland President Shane MacDonald MPS said that the move will encourage more Queenslanders to make influenza vaccination a part of their regular health care.

“All Queensland age groups have the lowest or second-lowest influenza vaccination coverage of any state or territory this year,” Mr MacDonald said.

“Particularly at risk are young children, of which less than 20 per cent are vaccinated against influenza in 2023. Vaccination rates among Queenslanders aged 5 to 15 years is the lowest in Australia, sitting at just 11.1 per cent.

“We have already seen the deadly impact of low vaccination rates across the country, and if we don’t act now it will only get worse.

“Removing cost barriers and giving Queenslanders greater access to vaccines through community pharmacies is a great first step to improving vaccine uptake,” Mr MacDonald said.

“Pharmacists are able to vaccinate patients 6 months and over, meaning many families can come into their pharmacy together for their flu vaccines.

“With the flu season now in full swing, we need to do everything we can to protect Australian children by increasing access to vaccination and providing Queensland families with optimal protection against this deadly disease.

“As pharmacists we have demonstrated the crucial role we continue to play in protecting the health of Australians. We must do better than this to protect the most vulnerable in our communities.

“Pharmacists are practicing in almost every community from Brisbane to Cape York, supporting the health and wellbeing of our patients.

“Our message to all Queenslanders is simple, visit your local pharmacist and get your influenza vaccine,” Mr MacDonald concluded.  

 

Data from NCIRS (accessed 17 July 2023)

https://ncirs.org.au/influenza-vaccination-coverage-data

 

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

The Pharmaceutical Society of Australia is the only national peak body that represents all of Australia’s pharmacists across all practice settings. We want every Australian to have access to the best healthcare, and this must include optimising access to pharmacists’ knowledge and medicines expertise at the forefront of our healthcare system.

 

More from this category

  • Medical Health Aged Care
  • 20/09/2024
  • 09:18
Dementia Australia

Time to act now – Australia’s opportunity to lead action on dementia

This Dementia Action Week, the need for urgent and sustained action by communities and governments at all levels to increase their awareness and understanding of dementia has never been clearer. Three publications released this week – a discussion paper from Dementia Australia, Neuroscience Research Australia (NeuRA) and the Lancet Regional Health-Western Pacific Journal series and the World Alzheimer’s Report 2024 from Alzheimer’s Disease International – provide compelling evidence for the critical need to urgently address the issues people living with dementia face. Dementia Australia CEO Professor Tanya Buchanan said the new publications highlight the enormity and impact of dementia in…

  • Medical Health Aged Care
  • 20/09/2024
  • 08:33
Palliative Care Australia

Greater access to care at home welcome, roll out and implementation will be critical to success

News of greater support for older Australians to be cared for at home recognises the wishes of older Australians and the complexity of care…

  • Contains:
  • Medical Health Aged Care
  • 20/09/2024
  • 06:26
Zenas BioPharma

Zenas BioPharma Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering

WALTHAM, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced that the underwriters of its previously announced upsized initial public offering of 13,235,294 shares of its common stock, which closed on September 16, 2024, exercised in full their option to purchase an additional 1,985,294 shares at the initial public offering price of $17.00 per share. After giving effect to the full exercise of the underwriters’ option to purchase additional shares, which closed on September 19,…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.